Psychedelic Psychiatry's Brave New World.
David Nutt, David Erritzøe, Robin Carhart-Harris
Cell April 1, 2020 DOI: 10.1016/j.cell.2020.03.020 (opens in new tab) via PubMed
Summary
AI-generated from the abstractFollowing a decades-long global halt in psychedelic research, new investigations into drugs like psilocybin that act on the 5-HT2A receptor are showing promise for treating serious psychiatric disorders, including depression and addiction. Neuroscience and clinical studies are yielding exciting results in this area.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Anxiety Depression Psychedelic-assisted therapy PTSD |
| Keywords | Psychedelics Therapeutic settings Guided sessions Psychedelic treatment |
| Citations | 330 |
| Key finding | Psilocybin and other 5-HT2A receptor agonists show promise for treating depression and addiction. |
Abstract
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.